{"id":"tralokinumab-tcs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-13 is a cytokine involved in the pathogenesis of atopic dermatitis. By inhibiting IL-13, tralokinumab reduces inflammation and improves symptoms. When combined with TCS, it enhances the anti-inflammatory effect.","oneSentence":"Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:25.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT03160885","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-06-12","conditions":"Atopic Dermatitis","enrollment":794},{"nctId":"NCT04587453","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2020-10-27","conditions":"Atopic Dermatitis","enrollment":106},{"nctId":"NCT03131648","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-05-30","conditions":"Atopic Dermatitis","enrollment":802},{"nctId":"NCT03761537","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-13","conditions":"Atopic Dermatitis","enrollment":277}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tralokinumab + TCS","genericName":"Tralokinumab + TCS","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}